Trial failure may signal the end for gamma secretase blockers

07/25/2013 | HealthDay News

Cognitive ability of clinical trial participants with mild to moderate Alzheimer's disease declined faster in the group taking gamma secretase-blocker semagacestat than in the placebo group, researchers report in The New England Journal of Medicine. The drug, designed to block an enzyme that makes beta amyloid plaques in the brain, worked as designed in early human and animal trials but failed to improve thinking skills in this trial.

View Full Article in:

HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ